New report from Clarivate Analytics highlights India as an emerging hub for biologics and biosimilars

London, UK, and New Delhi, India, December 16, 2019 – Clarivate Analytics plc (NYSE:CCC;CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, has released a new report together with the Department of Biotechnology (DBT), Biotechnology Industry Research Assistance Council (BIRAC) and ABLE (Association of Biotechnology Led Enterprises). Entitled ‘India: The emerging hub for biologics and biosimilars’, the report features analysis based on insights from Cortellis Deals Intelligence™ and Cortellis Competitive Intelligence™, and it can be downloaded here.

The report was released at the Global Bio-India 2019 in New Delhi on 21 November by Dr. Harsh Vardhan, Union Minister for Science and Technology, Earth Sciences, and Health and Family Welfare, Shri. Dharmendra Pradhan, Minister for Petroleum & Natural Gas and Steel, Dr. Renu Swarup, Secretary, DBT and other luminaries including Prof. Vinod K. Paul, Member NITI Aayog and Dr. Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon Limited.

 

The report was released at Global Bio-India 2019

 

The report examines the transformation of the pharmaceutical/biotech industry from small molecule therapeutics to biotherapeutics (biologics and biosimilars), driven by unmet clinical needs, the inherent advantages of biotherapeutics, and commercial potential. Of the top 10 blockbuster molecules in 2018, only two were small molecule therapeutics and eight were biological therapeutics.

The Indian pharmaceutical/biotech industry is well placed to capitalize on the substantial opportunity offered by biotherapeutics and includes companies with an extensive pipeline of biosimilars under active development.  So far, Indian pharmaceutical companies have launched 123 biosimilars and currently have 201 active biosimilars covering multiple indications in the development pipeline. It is likely that drug development will continue to accelerate thanks to the steps taken by the government of India to support the biopharmaceutical industry with the necessary infrastructure, funding, global collaborations to bridge the technical knowledge gap, and further development of regulatory guidelines.

Dr. Renu Swarup, Secretary, Department of Biotechnology said, “India is predicted to be one of the world’s ‘fastest-growing bio-hubs’ in the next few years. India’s growing biosimilars industry is the primary driver of this growth. India has 95 approved biosimilars in the domestic market, more than any other country, and market penetration, which is currently relatively low and expected to increase quickly in coming years with the increase in demand by middle class patients.”

Kiran Mazumdar, Chairperson and Managing Director, Biocon Limited, said, “Technological innovation, coupled with economies of scale, are driving India’s emergence as a global hub for biologics and biosimilars. We are already serving the needs of millions of patients globally, by assuring the supply of safe and efficacious biosimilars on an embedded platform of affordability. In enabling affordable access to high quality biosimilars worldwide, India’s biopharma sector can emulate the global leadership achieved in generic drugs and vaccines.”

Dr. Cyrus S. Poonawalla, Chairman and Managing Director, Serum Institute of India, said, “India’s contribution and heft in the health sector is growing through novel technologies and innovative science, supported by economies of scale and cutting-edge manufacturing infrastructure to drive new frontiers in health science.”

“Efforts by industry and the government will help position India as a leader in biotechnology-based research and a hub for biotech innovation and commercialization,” said Arvind Pachhapur, Vice President, Clarivate Analytics. “We are honoured to support these efforts to help accelerate the pace of innovation in the region.”

For further insight into the biosimilars and biologics market, please download the report here: http://bit.ly/2ODNJly

#  #  #

About Cortellis
Cortellis™, a Clarivate Analytics solution, gives life to science by unlocking the hidden insights in data by curating broad and deep sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation. For more information, please visit clarivate.com/cortellis.

About Clarivate Analytics
Clarivate Analytics™ is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. We have built some of the most trusted brands across the innovation lifecycle, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. Today, Clarivate Analytics is on a bold entrepreneurial mission to help customers reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.

Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

Media contact
Neha Kapoor
HighViz PR
neha.kapoor@highvizpr.com

+91-8447557680

 

Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
close